SAN ANTONIO –Roche/Genentech Inc. reported updated overall survival data from the pivotal Phase III CLEOPATRA trial showing a 34% reduction in risk of death for the Perjeta/Herceptin/chemotherapy combination that received full approval from FDA in June based on progression-free survival data, at the San Antonio Breast Cancer Symposium Dec. 7.
Final Perjeta Overall Survival Data Delayed By Its Efficacy
Overall survival results from the CLEOPATRA study, which produced the progression-free survival data that supported FDA’s decision in June to give Perjeta full approval for use in combination with Herceptin and chemotherapy, were reported at the San Antonio Breast Cancer Symposium Dec. 7.